GlassScriptPhysician profile
Chirin Orabi
NPI 1124479159
$655.18
in general payments reported to CMS, 2019-2025
14 companies · $16.52 in 2025
The $16.52 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $258 · 2023: $27.59 · 2024: $90.14 · 2025: $16.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $134.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $95.73 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.01 | 2019-2020 | |
| Glaxosmithkline, LLC. | $66.73 | 2019-2025 | Nucala |
| Inari Medical, INC. | $63.52 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| La Jolla Pharmaceutical Company | $57.31 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.16 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.52 | 2019-2020 | |
| Vifor Pharma, INC. | $40.97 | 2019 | |
| United Therapeutics Corporation | $32.06 | 2019 | |
| Inspire Medical Systems, INC. | $27.59 | 2023 | Inspire |
| Alexion Pharmaceuticals, INC. | $25.82 | 2020 | |
| Portola Pharmaceuticals, LLC | $25.01 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $24.39 | 2020 | |
| Paratek Pharmaceuticals, INC. | $17.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chirin Orabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.